Dentsply Sirona Expands U.S. Digital Dentistry Reach With Midwest Deal
XRAY expands its U.S. distribution reach through Midwest Dental, aiming to boost digital dentistry adoption and broaden access to its technology portfolio.
XRAY - DENTSPLY SIRONA Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$12.50
DETAILS
HIGH:
$17.00
LOW:
$10.00
MEDIAN:
$11.50
CONSENSUS:
$12.50
UPSIDE:
42.05%
Stock News
Dentsply Sirona (NASDAQ: XRAY) secures covenant relief in debt amendments
What happened Dentsply Sirona Inc. (NASDAQ: XRAY) said on October 8, 2026, that lenders consented to amendments to its revolving credit facility and related note agreements. The company entered the Third Amendment to Credit Agreement, dated September 30, 2026, and three Note Purchase Agreement Amendments for the 2015, 2016 and 2019 notes. The amendments raise
Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio
MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S.
Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement
The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona's North American dealer network and giving more customers access to its products and technology. The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona's North American dealer network and giving more customers access to its products and technology.
DENTSPLY SIRONA (NASDAQ:XRAY) Reaches New 1-Year Low – Time to Sell?
Shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY - Get Free Report) hit a new 52-week low on Friday. The company traded as low as $9.36 and last traded at $9.38, with a volume of 9306449 shares. The stock had previously closed at $10.14. Analyst Upgrades and Downgrades Several brokerages recently commented on XRAY. Barrington Research
Engineers Gate Manager LP Boosts Stake in DENTSPLY SIRONA Inc. $XRAY
Engineers Gate Manager LP boosted its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) by 451.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,810 shares of the medical instruments supplier's stock after acquiring an additional
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now
XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure
XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.
Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference
CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET.
Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities
"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonality effect," a crowded AI trade, a complicated geopolitical picture, and a steady rise in crude oil as components he sees leading a lasting bond rally.
New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence
New system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.
Empowered Funds LLC Grows Stake in DENTSPLY SIRONA Inc. $XRAY
Empowered Funds LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ: XRAY) by 515.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,601 shares of the medical instruments supplier's stock after acquiring an additional 106,024 shares during the
DENTSPLY SIRONA Q2 Earnings Call Highlights
DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.
XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.
Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 Earnings
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript
DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript
Dentsply International (XRAY) Beats Q2 Earnings and Revenue Estimates
Dentsply International (XRAY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.52 per share a year ago.
Dentsply Sirona Reports Second Quarter 2026 Results
News Summary Reported net sales of $898 million Delivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18 Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%, adjusted EPS of $0.52 Announced expanded partnership with Medline Sinclair, broadening access to Connected Technology Solutions portfolio across Canada Repurchased 1.3 million shares of common stock during the quarter Reiterates 2026 outlook for net sales and adjusted EPS CHARLOTTE, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2026.
Arkadios Wealth Advisors Purchases New Stake in DENTSPLY SIRONA Inc. $XRAY
Arkadios Wealth Advisors acquired a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 74,961 shares of the medical instruments supplier's stock, valued at approximately $870,000. Several other large investors also recently made
Price Targets
Dentsply Sirona price target lowered to $10 from $14 at Leerink
$10.00
(was $8.43)
Leerink Partners
Dentsply Sirona price target lowered to $12 from $14 at Piper Sandler
$12.00
(was $8.69)
Piper Sandler
Dentsply Sirona price target lowered to $10 from $13 at BMO Capital
$10.00
(was $10.14)
Vik Chopra
·
BMO Capital
Dentsply Sirona price target raised to $11 from $9 at Barclays
$11.00
(was $10.92)
Barclays
Dentsply Sirona price target lowered to $15 from $17 at Barrington
$15.00
(was $11.87)
Barrington
Dentsply Sirona price target raised to $13 from $12 at BMO Capital
$13.00
(was $12.04)
BMO Capital
Dentsply Sirona price target raised to $14 from $13 at Piper Sandler
$14.00
(was $13.49)
Piper Sandler
Dentsply Sirona initiated with a Market Perform at BMO Capital
$12.00
(was $11.78)
BMO Capital
Dentsply Sirona price target lowered to $9 from $12 at Barclays
$9.00
(was $9.64)
Barclays
Dentsply Sirona price target lowered to $17 from $18 at UBS
$17.00
(was $11.38)
UBS
Dentsply Sirona price target lowered to $16 from $17 at UBS
$16.00
(was $12.21)
Kevin Caliendo
·
UBS
Dentsply Sirona price target raised to $14 from $13 at Mizuho
$14.00
(was $12.21)
Mizuho Securities
Dentsply Sirona price target lowered to $12 from $14 at Baird
$12.00
(was $11.39)
Robert W. Baird
Dentsply Sirona initiated with an Underweight at Barclays
$12.00
(was $11.10)
Barclays
Dentsply Sirona price target lowered to $13 from $16 at Mizuho
$13.00
(was $10.99)
Mizuho Securities
Dentsply Sirona price target lowered to $13 from $15 at Stifel
$13.00
(was $11.16)
Stifel Nicolaus
Dentsply Sirona price target lowered to $23 from $24 at UBS
$23.00
(was $13.12)
UBS
Dentsply Sirona price target lowered to $13 from $17 at Evercore ISI
$13.00
(was $12.33)
Elizabeth Anderson
·
Evercore ISI
Dentsply Sirona price target lowered to $18 from $21 at Barrington
$18.00
(was $12.81)
Michael Petusky
·
Barrington
Dentsply Sirona downgraded to Equal Weight from Overweight at Morgan Stanley
$14.00
(was $12.55)
Erin Wright
·
Morgan Stanley